Cost-Effectiveness of Point-of-Care C-Reactive Protein Tests for Respiratory Tract Infection in Primary Care in England

Advances in Therapy

Volumn 32, Issue 1, 2015, Pages 69-85

  Hunter, Rachael ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antibiotics; C reactive protein; Cost effectiveness; CRP test; Primary care; Quality adjusted life years; Respiratory tract infection

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; C REACTIVE PROTEIN TEST KIT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION TREE; ECONOMIC EVALUATION; FEMALE; HUMAN; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; MEDICAL PRACTICE; NURSE; POINT OF CARE TESTING; PRESCRIPTION; PRIMARY MEDICAL CARE; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY TRACT INFECTION; SENSITIVITY ANALYSIS; STANDARD; UNITED KINGDOM; BLOOD; COMPARATIVE STUDY; ECONOMICS; ENGLAND; HEALTH CARE QUALITY; HEALTH SERVICE; PERSONNEL MANAGEMENT; PREVENTION AND CONTROL; PRIMARY HEALTH CARE; PROCEDURES; QUALITY OF LIFE; RESPIRATORY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; C-REACTIVE PROTEIN; COST-BENEFIT ANALYSIS; ENGLAND; HUMANS; MEDICAL OVERUSE; POINT-OF-CARE TESTING; PRIMARY HEALTH CARE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RESPIRATORY TRACT INFECTIONS; STAFF DEVELOPMENT; STANDARD OF CARE;

EID: 84925518168     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0180-x     Document Type: Article

References (21)

1. Respiratory tract infections—antibiotic prescribing. NICE clinical guideline 69. NICE; London, UK; 2008. Available from: http://www.nice.org.uk/guidance/cg69/. Accessed 1 June 2014.
2. Public Health England: English surveillance programme for antimicrobial utilisation and resistance (ESPAUR). Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/362374/ESPAUR_Report_2014__3_.pdf. Accessed 1 June 2014.
3. Butler C, Hood K, Verheij T, et al. Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries. BMJ. 2009;338:b2242.
4. Department of Health and Department for Environment, Food & Rural Affairs: UK Five Year Antimicrobial Resistance Strategy 2013 to 2018. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf. Accessed 1 June 2014.
5. Huang Y, Chen R, Wu T, et al. Association between point-of-care CRP testing and antibiotic prescribing in respiratory tract infections: a systematic review and meta-analysis of primary care studies. Br J Gen Pract. 2013;63(616):e787–94.
6. Cals JW, Butler CC, Hopstaken RM, Hood K, Dinant GJ. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ. 2009;338:b1374.
7. Little P, Stuart B, Francis N, et al. Effects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: a multinational, cluster, randomised, factorial, controlled trial. Lancet. 2013;382(9899):1175–82.
8. Oppong R, Jit M, Smith RD, et al. Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions. Br J Gen Pract. 2013;63(612):e465–71.
9. Cals JW, de Bock L, Beckers PJ, et al. Enhanced communication skills and C-reactive protein point-of-care testing for respiratory tract infection: 3.5-year follow-up of a cluster randomized trial. Ann Fam Med. 2013;11(2):157–64.
10. Cals JW, Schot MJ, de Jong SA, Dinant GJ, Hopstaken RM. Point-of-care C-reactive protein testing and antibiotic prescribing for respiratory tract infections: a randomized controlled trial. Ann Fam Med. 2010;8(2):124–33.
11. Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF) 67. BMJ Publishing Group Ltd and Royal Pharmaceutical Society; 2014.
12. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2011. ISBN 978-019-852662-9.
13. Alere: Afinion™ AS100 Analyzer and tests. Available from: http://www.alere.co.uk/search/?q=afinion. Accessed 1 June 2014.
14. Health and Social Care Information Centre: Prescription Cost Analysis, England—2013. Available from http://www.hscic.gov.uk/catalogue/PUB13887. Accessed 1 June 2014.
15. Curtis L. Unit costs of health and social care 2013. Personal social services research unit (PSSRU). Canterbury: University of Kent; 2014.
16. NHS reference costs: financial year 2012 to 2013. Department of Health; 2014.
17. Pneumonia: diagnosis and management of community- and hospital-acquired pneumonia in adults. NICE; London, UK; 2014. Draft guideline available from: http://www.nice.org.uk/guidance/gid-cgwave0607/resources/pneumonia-guideline-consultation-nice-guideline2. Accessed 1 June 2014.
18. Cals JW, Ament AJ, Hood K, et al. C-reactive protein point of care testing and physician communication skills training for lower respiratory tract infections in general practice: economic evaluation of a cluster randomized trial. J Eval Clin Pract. 2011;17(6):1059–69.
19. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. Discussion paper 172. Centre for Health Economics, University of York; 1999.
20. Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005;14:339–47.
21. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779–87.